Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. - Wikidata - wikimedia - TriplyDB

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

http://www.wikidata.org/entity/Q34650239

about

Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Drugs derived from phage display: from candidate identification to clinical practice On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye.Modern Technologies for Creating Synthetic Antibodies for Clinical application.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Using current data to define new approach in age related macular degeneration: need to accelerate translational research.Emerging biological therapies for age-related macula degeneration.EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV.Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.Recombinant human VEGF165b inhibits experimental choroidal neovascularization Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Pseudoxanthoma elasticum, ocular manifestations, complications and treatment.ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol.Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor Ranibizumab for the treatment of degenerative ocular conditions.Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis Aflibercept for the treatment of age-related macular degeneration.VEGF-A165b is cytoprotective and antiangiogenic in the retina Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration The effect of bevacizumab on corneal neovascularization in rabbits.Micro-patterned drug delivery device for light-activated drug release.Anti-VEGF agents for age-related macular degeneration.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials.Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration.Systemic safety of anti-VEGF drugs: a commentary.Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Critical appraisal of ranibizumab in the treatment of diabetic macular edema.Targeting Neovascularization in Ischemic Retinopathy: Recent Advances Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

P2860

Q26823757-70760F92-47DA-4890-920C-8E2AD59466C4 Q27007101-A0921F80-F7DB-41AB-AFA1-F364EE68641C Q27025624-E6C0958C-2289-4825-958F-A1C1AF40AA79 Q28292764-37B09335-2C37-4BC2-8247-B04F25E2B0E9 Q28552652-DDC3AB6C-EB9C-48BD-9BFA-718F23F92689 Q28740612-50357E82-F4CC-4A45-9718-D4F718ADD4B2 Q30424219-AF7CF54E-F05F-484E-93EB-7A8FC81C0BF9 Q30467308-73B8CAF7-9BC8-40B2-8BA1-6478A4628332 Q30490738-9C415C20-2ECA-4593-A2AB-3CB9AEE67F4B Q30843382-6925D9FE-920A-443B-BDE5-A8D3F5C2DD9E Q33224360-E7F4707C-4E4E-4978-A553-2B4E8632BE95 Q33237979-8C250869-2FCD-4F87-B1B9-395549904BDB Q33492369-6761FFDE-090F-466C-8547-5A54CDD43F13 Q33519532-7CE2EBF0-7088-4040-BDE7-43D48C53A8EB Q33541827-9326CB97-16DA-4ECF-96FA-8C4AA33B375F Q33571004-9DC7CD8C-249B-4E5E-96DD-C617669B0841 Q33740152-FEFB36B5-E422-4532-8ADC-3C64697E850B Q33783912-4AE07AE5-1380-4AB4-BA84-6E536325360C Q33795198-C88914C0-0F63-4CE4-A1BE-AA7F09F6BECE Q33819829-C28FFF92-44B0-43FE-9119-8236370F3222 Q33831237-0500E970-3D69-48FB-815D-BEDE018DAF94 Q33912485-24361092-58E7-4A59-9706-1C657496093F Q33939215-53345415-0F80-42F1-9060-637C3403F762 Q34022623-729243FA-8EF9-4FDA-AF0F-1CC392F07DB8 Q34043286-FBB5A682-D44E-43AE-871D-9CF5FFD2BB70 Q34044322-8A9EFA9A-5792-4898-B375-4FFC52F01685 Q34086350-C1485F8C-EB07-44F0-AF4C-6A16D23FBF50 Q34088934-3FEF8E10-8C09-439F-B1C8-A6014E031EE8 Q34092454-A0946D9D-08EC-44AF-9177-EAE95B7B6189 Q34282654-46D356C0-AEA4-4F6A-AA0F-EF9D05C80C65 Q34449898-A7806A7A-15A8-41B6-8D83-1A2EC03B27B2 Q34452811-A665622E-EE7B-459F-A7E2-71E776D1E1DA Q34554270-987BBC75-6346-4880-91E1-F26A7BBC6B88 Q34557530-03347000-668A-4A91-AD03-2D0A98309656 Q34642583-89819A42-29C7-497B-A5F7-A18A5AD1F3DC Q34658699-9509BA9F-CAEE-48EB-A169-CEF58F5F06F9 Q34740219-5911A668-920D-4AE0-9DEA-9FDB88586328 Q34803171-7B97437F-D784-422F-944F-053A7DCDD1B9 Q34972210-64AFF3BD-6A19-4B88-877C-CBEB7A778D23 Q35015882-B8C9E4CA-F142-409E-A9CD-546C2FC1866F

P2860

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

http://www.wikidata.org/entity/Q34650239

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Preclinical pharmacokinetics o ...... e intravitreal administration.

@ast

Preclinical pharmacokinetics o ...... e intravitreal administration.

@en

Preclinical pharmacokinetics of Ranibizumab

@nl

type

label

Preclinical pharmacokinetics o ...... e intravitreal administration.

@ast

Preclinical pharmacokinetics o ...... e intravitreal administration.

@en

Preclinical pharmacokinetics of Ranibizumab

@nl

prefLabel

Preclinical pharmacokinetics o ...... e intravitreal administration.

@ast

Preclinical pharmacokinetics o ...... e intravitreal administration.

@en

Preclinical pharmacokinetics of Ranibizumab

@nl

P1433

Q34650239-4B2F3A78-0358-4930-90E8-99845B833144

P1476

Q34650239-F8BB41EC-11F9-4C07-AB54-31F5B6D91810

P2093

Q34650239-0A06DB09-FD88-4A49-B97D-F2EE1CF84B2D

Q34650239-14E3B916-5CDC-4472-87D2-FB31A8ECAD81

Q34650239-439C344A-9AB0-48D6-94A9-766898FD2A46

Q34650239-B74AF7CF-48FF-408A-846D-266FE85AA611

Q34650239-E4967734-726B-49E1-BD5F-E0A0BDD39E25

P304

Q34650239-06B07F9A-214A-4179-B49A-F4F87D8654D1

P31

Q34650239-F337C11D-295C-4240-8F6E-99868D410030

P356

Q34650239-64CECAB8-D1FD-4898-A8C6-B35424AF83B1

P407

Q34650239-760148F5-9E22-44A9-8D7B-5E4F2D8C844A

P433

Q34650239-13D790D2-4A8B-4050-B7E0-3BADB12CD9A8

P478

Q34650239-95B04152-8C4A-4788-BEE3-B9599B4A10B4

P577

Q34650239-F695684B-93DE-44D7-A77D-CDDE0D9429F5

P5875

Q34650239-F1C13D21-FFF0-42F3-827A-980D87841BEB

P698

Q34650239-860B06B2-9D1F-4814-89B7-0C59E44C9469

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Preclinical pharmacokinetics o ...... e intravitreal administration.

@en

P2093

David Fei

http://www.w3.org/2001/XMLSchema#string

Jacques Gaudreault

http://www.w3.org/2001/XMLSchema#string

Jeriza Rusit

http://www.w3.org/2001/XMLSchema#string

Pamela Suboc

http://www.w3.org/2001/XMLSchema#string

Vanessa Shiu

http://www.w3.org/2001/XMLSchema#string

P304

726-733

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.04-0601

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8061123

http://www.w3.org/2001/XMLSchema#string

P698

15671306

http://www.w3.org/2001/XMLSchema#string